165 related articles for article (PubMed ID: 25849335)
21. Suppressive Role of Tissue Factor Pathway Inhibitor-α in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength.
Thomassen S; Mastenbroek TG; Swieringa F; Winckers K; Feijge MAH; Schrijver R; Cosemans JMEM; Maroney SA; Mast AE; Hackeng TM; Heemskerk JWM
Thromb Haemost; 2018 Mar; 118(3):502-513. PubMed ID: 29452445
[TBL] [Abstract][Full Text] [Related]
22. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor.
Fischer EG; Riewald M; Huang HY; Miyagi Y; Kubota Y; Mueller BM; Ruf W
J Clin Invest; 1999 Nov; 104(9):1213-21. PubMed ID: 10545520
[TBL] [Abstract][Full Text] [Related]
23. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
[TBL] [Abstract][Full Text] [Related]
24. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein.
Hamik A; Setiadi H; Bu G; McEver RP; Morrissey JH
J Biol Chem; 1999 Feb; 274(8):4962-9. PubMed ID: 9988740
[TBL] [Abstract][Full Text] [Related]
25. Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces.
Le DT; Rapaport SI; Rao LV
J Biol Chem; 1992 Aug; 267(22):15447-54. PubMed ID: 1639786
[TBL] [Abstract][Full Text] [Related]
26. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa.
Camerer E; Huang W; Coughlin SR
Proc Natl Acad Sci U S A; 2000 May; 97(10):5255-60. PubMed ID: 10805786
[TBL] [Abstract][Full Text] [Related]
27. Fibronectin-adherent monocytes express tissue factor and tissue factor pathway inhibitor whereas endotoxin-stimulated monocytes primarily express tissue factor: physiologic and pathologic implications.
Bajaj MS; Ghosh M; Bajaj SP
J Thromb Haemost; 2007 Jul; 5(7):1493-9. PubMed ID: 17470199
[TBL] [Abstract][Full Text] [Related]
28. Recombinant full-length tissue factor pathway inhibitor fails to bind to the cell surface: implications for catabolism in vitro and in vivo.
Ho G; Narita M; Broze GJ; Schwartz AL
Blood; 2000 Mar; 95(6):1973-8. PubMed ID: 10706863
[TBL] [Abstract][Full Text] [Related]
29. A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1.
Bendz B; Andersen TO; Sandset PM
Thromb Res; 2000 Mar; 97(6):463-72. PubMed ID: 10704656
[TBL] [Abstract][Full Text] [Related]
30. Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa.
Aberg M; Wickström M; Siegbahn A
Thromb Res; 2008; 122(2):191-202. PubMed ID: 18031796
[TBL] [Abstract][Full Text] [Related]
31. Receptor-mediated endocytosis of coagulation factor Xa requires cell surface-bound tissue factor pathway inhibitor.
Ho G; Toomey JR; Broze GJ; Schwartz AL
J Biol Chem; 1996 Apr; 271(16):9497-502. PubMed ID: 8621621
[TBL] [Abstract][Full Text] [Related]
32. Tissue Factor/ FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1).
Aberg M; Johnell M; Wickström M; Siegbahn A
Thromb Res; 2011 Feb; 127(2):141-8. PubMed ID: 21168190
[TBL] [Abstract][Full Text] [Related]
33. Analysis of tissue factor expression in various cell model systems: cryptic vs. active.
Kothari H; Pendurthi UR; Rao LV
J Thromb Haemost; 2013 Jul; 11(7):1353-63. PubMed ID: 23621622
[TBL] [Abstract][Full Text] [Related]
34. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat.
Han X; Girard TJ; Baum P; Abendschein DR; Broze GJ
Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2563-7. PubMed ID: 10521388
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa.
Ollivier V; Chabbat J; Herbert JM; Hakim J; de Prost D
Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1374-81. PubMed ID: 10807756
[TBL] [Abstract][Full Text] [Related]
36. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
Tinholt M; Vollan HK; Sahlberg KK; Jernström S; Kaveh F; Lingjærde OC; Kåresen R; Sauer T; Kristensen V; Børresen-Dale AL; Sandset PM; Iversen N
Breast Cancer Res; 2015 Mar; 17(1):44. PubMed ID: 25882602
[TBL] [Abstract][Full Text] [Related]
37. Study of factor VII, tissue factor pathway inhibitor and monocyte tissue factor in noninsulin-dependent diabetes mellitus.
El-Ghoroury EA; El-Din HG; Abdel-Kader M; Ragab S
Blood Coagul Fibrinolysis; 2008 Jan; 19(1):7-13. PubMed ID: 18180609
[TBL] [Abstract][Full Text] [Related]
38. Tissue factor pathway inhibitor (TFPI)--an update.
Sandset PM
Haemostasis; 1996 Oct; 26 Suppl 4():154-65. PubMed ID: 8979119
[TBL] [Abstract][Full Text] [Related]
39. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.
Taniguchi T; Kakkar AK; Tuddenham EG; Williamson RC; Lemoine NR
Cancer Res; 1998 Oct; 58(19):4461-7. PubMed ID: 9766679
[TBL] [Abstract][Full Text] [Related]
40. Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model.
Almus FE; Rao LV; Rapaport SI
Arterioscler Thromb; 1993 Jan; 13(1):105-11. PubMed ID: 8422331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
